{
    "clinical_study": {
        "@rank": "139466", 
        "arm_group": [
            {
                "arm_group_label": "Xeloda", 
                "arm_group_type": "Active Comparator", 
                "description": "Subjects will receive Xeloda until progression"
            }, 
            {
                "arm_group_label": "QYHJ Granules", 
                "arm_group_type": "Experimental", 
                "description": "patients will receive QYHJ Granules until progression"
            }
        ], 
        "brief_summary": {
            "textblock": "Primary End Point:\n\n      - To compare the overall survival (OS) using QYHJ Granules or Xeloda as the second therapy\n      in patients with metastatic pancreatic cancer.\n\n      Secondary End Points:\n\n        -  Compare clinical efficacy by other measures including PFS,tumor response,and changes in\n           quality of life (QOL) between these two groups.\n\n        -  Examine the feasibility and assess the side effects of treatment using QYHJ Granules in\n           patients with metastatic pancreatic cancer."
        }, 
        "brief_title": "QYHJ Granules Versus Xeloda in Metastatic Pancreatic Cancer", 
        "completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Metastatic Pancreatic Cancer", 
        "condition_browse": {
            "mesh_term": "Pancreatic Neoplasms"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Histologically/cytologically confirmed metastatic pancreatic adenocarcinoma.\n\n          -  Patients have failed from the prior chemotherapy without Xeloda. Adjuvant\n             chemotherapy containing Xeloda and 6 months before recruitment is included.\n\n          -  Patients haven't taken QYHJ Granules before. Prior exposure to Traditional Chinese\n             Medicine not based on QYHJ Formula is allowed provided that at least one week washout\n             time is given prior to initiation of experimental treatment.\n\n          -  ECOG performance status 0, 1 or 2.\n\n          -  Measurable disease by RECIST criteria must be present. Bone scan abnormalities alone\n             will not be accepted as measurable disease. Lytic lesions seen on plain radiographs\n             will not be accepted as measurable disease but will be evaluated in conjunction with\n             bone scan abnormalities. Pure blastic bone metastases will not be accepted as\n             measurable disease. Pleural or peritoneal effusions will not be accepted as\n             measurable disease. Irradiated lesions are not considered measurable.\n\n          -  Patients must not be pregnant. Serum beta-HCG will be checked in all premenopausal\n             patients.\n\n          -  Patients must have adequate organ functions reflected by the laboratory criteria\n             below: neutrophil counts \u2265 1.5\u00d7109 /L, platelet count \u2265 100 x 109/L,  hemoglobin \u2265 85\n             g/L, Serum creatinine < 2.0 mg/dL, Bilirubin < 1.5 mg/dL, ALT < 3 x normal, albumin\n             >30g/L.\n\n          -  Age \u2265 18.\n\n          -  Prior local therapy, e.g., TACE or radiation, is allowed provided that at least 4\n             weeks washout time is given.\n\n          -  Concomitant bisphosphonates are allowed for patients with bone metastases. Patients\n             with jaundice must have a biliary drainage decompression operation before\n             recruitment.\n\n          -  Ability to understand and the willingness to sign a written informed consent.\n\n          -  Subjects who have a life expectancy of at least 3 months.\n\n        Exclusion Criteria:\n\n          -  ECOG performance status 3 or 4.\n\n          -  Known central nervous system involvement and leptomeningeal disease.\n\n          -  Previous Xeloda-based chemotherapy  \uff08except usage for Adjuvant chemotherapy and 6\n             months before recruitment\uff09.\n\n          -  Prior treatment with QYHJ Granules.\n\n          -  Other serious illness or condition including cardiac disease including congestive\n             heart failure (New York Heart Association Classification III or IV),unstable angina,\n             myocardial infarction within the past six months, severe arrhythmia.\n\n          -  Concurrent infection requiring intravenous antibiotics, active HIV infection/HIV\n             disease, psychiatric disorders, drug abuse.\n\n          -  Known allergies to the QYHJ or Xeloda.\n\n          -  Pregnant or lactating females. Serum pregnancy test to be assessed within 7 days\n             prior to study treatment start, or within 14 days with a confirmatory urine pregnancy\n             test within 7 days prior to study treatment start. Men and women of childbearing\n             potential not using effective means of contraception.\n\n          -  Known other non-adenocarcinoma pathological type.\n\n          -  Other primary tumour (including primary brain tumours) within the last 5 years prior\n             to enrollment, except for adequately treated carcinoma in situ of the cervix or basal\n             cell skin cancer.\n\n          -  Inability to take oral medication, prior surgical procedures affecting absorption or\n             unwilling to take the Traditional Chinese Medicine.\n\n          -  Patiens who are suffering from diarrhea.\n\n          -  Subjects with poor compliance."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "60", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 16, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01796782", 
            "org_study_id": "TCM-002"
        }, 
        "intervention": [
            {
                "arm_group_label": "Xeloda", 
                "description": "Xeloda dose is calculated according to body surface area.The recommended dose  is 1000 mg/m\u00b2 administered orally twice daily (morning and evening; equivalent to 2000 mg/m\u00b2 total daily dose) for 2 weeks followed by a 1-week rest period given as 3-week cycles", 
                "intervention_name": "Xeloda", 
                "intervention_type": "Drug", 
                "other_name": "Capecitabine"
            }, 
            {
                "arm_group_label": "QYHJ Granules", 
                "description": "1-4 bags bid , days 1-42, every 6 weeks", 
                "intervention_name": "QYHJ Granules", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Capecitabine"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "February 20, 2013", 
        "number_of_arms": "2", 
        "official_title": "A Prospective, Randomized, Open-label, Phase II Study of QYHJ Granules Versus Xeloda in the Second-line Treatment of Patients With Metastatic Pancreatic Cancer", 
        "overall_official": [
            {
                "affiliation": "shanghai cancer center, fudan university", 
                "last_name": "zhen Chen, M.D.", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "shanghai cancer center, fudan university", 
                "last_name": "lu ming Liu, M.D.", 
                "role": "Study Director"
            }
        ], 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "China: Ethics Committee", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "August 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "overall survival (OS)", 
            "safety_issue": "No", 
            "time_frame": "up to 3 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01796782"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Fudan University", 
            "investigator_full_name": "liu lu ming", 
            "investigator_title": "professor", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "measure": "Progression free survival\uff08PFS\uff09", 
                "safety_issue": "No", 
                "time_frame": "up to 3 years"
            }, 
            {
                "measure": "Tumor response\uff08ORR\u3001DCR\uff09", 
                "safety_issue": "No", 
                "time_frame": "up to 3 years"
            }, 
            {
                "measure": "Clinical benefit rate \uff08CBR\uff09and QOL assessment", 
                "safety_issue": "No", 
                "time_frame": "up to 3 years"
            }, 
            {
                "measure": "Number of adverse events of QYHJ Formula", 
                "safety_issue": "Yes", 
                "time_frame": "up to 3 years"
            }
        ], 
        "source": "Fudan University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Fudan University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2013"
    }
}